This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at the recent approval of Eli Lilly and Incyte's Olumiant (baricitinib) and potential use in alopecia areata
Ticker(s): LLY, INCYWho's the expert?
Institution: Henry Ford Health
- Board-certified dermatologist and fellowship-trained dermatologist
- Faculty at Henry Ford Dept. of Dermatology.
- Authored several peer reviewed publications and has written multiple textbook chapters and served as an investigator on 40 clinical trials.
- Research interest includes aser and cosmetic procedures & vein treatment and sclerotherapy.
- Manages 300 patients with Alopecia Areata and prescribes olumiant to 10 patients.
Interview GoalThis conversation will focus on discussing the recent FDA Approval of Oluminant in treating patients with alopecia areata
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
